Want to see BDRX full AI Analyst Report?
BDRX Stock Chart & Stats
$1.65
-$0.08(-4.85%)
At close: 4:00 PM EDT
$1.65
-$0.08(-4.85%)
Day’s Range― - ―
52-Week Range$1.02 - $59.40
Previous Close$1.75
Volume25.39K
Average Volume (3M)260.97K
Market Cap
$6.53B
Enterprise Value-$6.77M
Total Cash (Recent Filing)$8.52M
Total Debt (Recent Filing)$60.89K
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Sep 11, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-536.25
Shares Outstanding828,923
10 Day Avg. Volume685,915
30 Day Avg. Volume260,967
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.03
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.95
Enterprise Value/Ebitda0.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$7.66K
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger Balance SheetA very low debt load and meaningful equity growth provide structural financial flexibility for a clinical-stage biotech. With limited leverage, the company can pursue R&D and clinical programs without immediate debt servicing risks, lengthening runway versus highly levered peers.
Year-over-year Reduced Cash BurnA material reduction in operating cash outflow demonstrates improving operational efficiency and pacing of clinical spend. If sustained, this durable trend reduces near-term funding frequency and dilution pressure, improving the company’s ability to execute multi-stage trials over months to years.
Capital Structure Reorg + Issuance AuthorityA completed share-capital reorganisation and broad allotment authority materially increases the firm's ability to raise equity capital and simplify ADS administration. This structural flexibility supports continued financing of clinical programs and strategic partnerships over the medium term.
Bears Say
Pre-commercial; Zero RevenueWith no product revenue, the company remains entirely dependent on external funding to sustain operations. This structural revenue absence means long-term viability hinges on successful clinical outcomes or continued financings, raising execution and dilution risk for investors over multiple quarters.
Continued Negative Cash GenerationOngoing negative operating and free cash flow indicate the business continues to consume capital despite improvement. Persistent burn necessitates periodic financings or asset monetization, which can dilute shareholders and constrain investment timing if capital markets tighten over the next several quarters.
Governance Friction / Shareholder ResistanceAdjourned meetings and rejection of critical resolutions signal governance and shareholder alignment issues. These structural frictions can slow strategic decisions, complicate planned financings or warrant issuances, and reduce managerial flexibility to execute long-term clinical or financing plans.
Biodexa Pharmaceuticals News
BDRX FAQ
What was Biodexa Pharmaceuticals’s price range in the past 12 months?
Biodexa Pharmaceuticals lowest stock price was $1.02 and its highest was $59.40 in the past 12 months.
What is Biodexa Pharmaceuticals’s market cap?
Biodexa Pharmaceuticals’s market cap is $6.53B.
When is Biodexa Pharmaceuticals’s upcoming earnings report date?
Biodexa Pharmaceuticals’s upcoming earnings report date is Sep 11, 2026 which is in 42 days.
How were Biodexa Pharmaceuticals’s earnings last quarter?
Biodexa Pharmaceuticals released its earnings results on Mar 27, 2026. The company reported -$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.001.
Is Biodexa Pharmaceuticals overvalued?
According to Wall Street analysts Biodexa Pharmaceuticals’s price is currently Overvalued.
Does Biodexa Pharmaceuticals pay dividends?
Biodexa Pharmaceuticals does not currently pay dividends.
What is Biodexa Pharmaceuticals’s EPS estimate?
Biodexa Pharmaceuticals’s EPS estimate is 0.
How many shares outstanding does Biodexa Pharmaceuticals have?
Biodexa Pharmaceuticals has 828,923 shares outstanding.
What happened to Biodexa Pharmaceuticals’s price movement after its last earnings report?
Biodexa Pharmaceuticals reported an EPS of -$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.514%.
Which hedge fund is a major shareholder of Biodexa Pharmaceuticals?
Currently, no hedge funds are holding shares in BDRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
Technical Analysis
―
Indaptus Therapeutics
―
InMed Pharmaceuticals
―
Enveric Biosciences
―
CNS Pharmaceuticals
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.06% Other Institutional Investors
99.94% Public Companies and
Individual Investors